{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:01:29Z","timestamp":1790744489501,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the past decade, many new agents have been introduced for the management of follicular lymphoma, and therapeutic strategies have evolved over time. The clinical benefits of the different treatments vary and, at the time of progression, are influenced by patient and disease characteristics, the duration of the interval from last treatment, and the nature of the treatments previously administered. Altogether, this results in a marked heterogeneity of clinical situations encountered during the treatment of these patients. Despite numerous trials performed in the field, there is no single standard of care for patients undergoing second-line treatment or beyond. Furthermore, patients recruited in these studies have characteristics that rarely represent the full spectrum of possible clinical presentations. Therefore, to optimally individualize treatment, all of the risks (short- and long-term) and benefits of the available options should be well known. Discussing the goals of therapy with the patient at each intervention is also critical in providing an optimal sequence of therapy.<\/jats:p>","DOI":"10.1182\/hematology.2020000156","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T04:08:47Z","timestamp":1607141327000},"page":"287-294","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["How do I sequence therapy for follicular lymphoma?"],"prefix":"10.1182","volume":"2020","author":[{"given":"Gilles","family":"Salles","sequence":"first","affiliation":[{"name":"Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"31","key":"2020121621262357600_B1","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA Study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020121621262357600_B2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: a translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2020121621262357600_B3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020121621262357600_B4","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"2020121621262357600_B5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. [published correction appears in Lancet Oncol. 2018;19(6):e283]","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"2020121621262357600_B6","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdw185","article-title":"Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL","volume":"27","author":"Koch","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"2020121621262357600_B7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","article-title":"NCCN guidelines insights: B-cell lymphomas, version 3.2019","volume":"17","author":"Zelenetz","year":"2019","journal-title":"J Natl Compr Canc Netw."},{"key":"2020121621262357600_B8","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol."},{"issue":"27","key":"2020121621262357600_B9","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"issue":"29","key":"2020121621262357600_B10","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020121621262357600_B11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ijrobp.2015.12.019","article-title":"Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I\u2013II follicular lymphoma: results of a multicenter study","volume":"94","author":"Ruella","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2020121621262357600_B12","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1097\/HS9.0000000000000160","article-title":"Rituximab with involved field irradiation for early-stage nodal follicular lymphoma: results of the MIR study","volume":"2","author":"Herfarth","year":"2018","journal-title":"HemaSphere"},{"issue":"4","key":"2020121621262357600_B13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"23","key":"2020121621262357600_B14","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM Study: influence of chemotherapy on efficacy and safety [published correction appears in J Clin Oncol. 2018;36(27):2815]","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020121621262357600_B15","first-page":"8023","article-title":"Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: updated results from the phase III Gallium Study [abstract]","volume-title":"J Clin Oncol","author":"Townsend","year":"2020"},{"issue":"14","key":"2020121621262357600_B16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"2020121621262357600_B17","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study [published correction appears in J Clin Oncol. 2018;36(26):2748]","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020121621262357600_B18","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel: an update","volume":"57","author":"Cheson","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2020121621262357600_B19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/bjh.15057","article-title":"A retrospective study of R-DHAP\/Ox for early progressing follicular lymphoma","volume":"183","author":"Ghione","year":"2018","journal-title":"Br J Haematol"},{"issue":"8","key":"2020121621262357600_B20","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"17","key":"2020121621262357600_B21","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020121621262357600_B22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2017.01.021","article-title":"Rituximab maintenance improves overall survival of patients with follicular lymphoma: individual patient data meta-analysis","volume":"76","author":"Vidal","year":"2017","journal-title":"Eur J Cancer"},{"issue":"13","key":"2020121621262357600_B23","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","article-title":"Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation","volume":"31","author":"Pettengell","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020121621262357600_B24","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","article-title":"Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study","volume":"96","author":"Le Gouill","year":"2011","journal-title":"Haematologica"},{"issue":"6","key":"2020121621262357600_B25","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020121621262357600_B26","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant research analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2020121621262357600_B27","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. [published correction appears in J Clin Oncol. 2016;34(12):1430]","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020121621262357600_B28","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"22","key":"2020121621262357600_B29","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA Trial. [published correction appears in J Clin Oncol. 2016;34(26):3230]","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020121621262357600_B30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"key":"2020121621262357600_B31","article-title":"Transformed lymphoma: what should I do now?","volume":"2020","author":"Smith","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"14","key":"2020121621262357600_B32","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","article-title":"How I treat early-relapsing follicular lymphoma","volume":"133","author":"Casulo","year":"2019","journal-title":"Blood."},{"issue":"3","key":"2020121621262357600_B33","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijrobp.2019.03.004","article-title":"Salvage treatment and survival for relapsed follicular lymphoma following primary radiation therapy: a collaborative study on behalf of ILROG","volume":"104","author":"Binkley","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2020121621262357600_B34","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2020121621262357600_B35","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"2020121621262357600_B36","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. [published correction appears in J Clin Oncol. 2019;37(16):1448]","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020121621262357600_B37","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. [published online ahead of print 23 December 2019]","author":"Dreyling","journal-title":"Am J Hematol"},{"key":"2020121621262357600_B38","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial [published online 6 October 2020]","author":"Morschhauser","journal-title":"Lancet Oncol"},{"issue":"17","key":"2020121621262357600_B39","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020121621262357600_B40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/10428190903503404","article-title":"Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study","volume":"51","author":"Johnston","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2020121621262357600_B41","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3324\/haematol.2012.069583","article-title":"Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"2020121621262357600_B42","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.31264","article-title":"Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR","volume":"124","author":"Sureda","year":"2018","journal-title":"Cancer"},{"key":"2020121621262357600_B43","first-page":"6","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines [abstract]","volume-title":"Blood","author":"Schuster","year":"2019"},{"key":"2020121621262357600_B44","author":"Dickinson","year":"2020"},{"key":"2020121621262357600_B45","first-page":"8008","article-title":"Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL)","volume-title":"J Clin Oncol","author":"Jacobson","year":"2020"},{"issue":"29","key":"2020121621262357600_B46","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/287\/1795048\/hem2020000156c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/287\/1795048\/hem2020000156c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:16:18Z","timestamp":1608315378000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/287\/474299\/How-do-I-sequence-therapy-for-follicular-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000156","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}